Urolithin A
Urolithin A is a highly potent postbiotic metabolite produced by the human gut microbiome from dietary ellagitannins found in pomegranates, berries, and nuts. It functions as a first-in-class inducer of mitophagy, the selective cellular process that clears damaged and dysfunctional mitochondria, thereby restoring cellular energy capacity, improving skeletal muscle strength, and addressing a primary hallmark of aging.
Key Takeaways
- •Acts as a direct and potent inducer of mitophagy, the targeted degradation of defective mitochondria, which prevents the age-related accumulation of dysfunctional organelles that drive cellular senescence.
- •Bypasses the natural microbiome lottery; because only about 30 to 40 percent of the human population possesses the specific gut bacteria required to synthesize Urolithin A from dietary precursors, direct supplementation ensures consistent and therapeutic systemic exposure.
- •Demonstrates significant clinical efficacy in improving skeletal muscle strength, endurance, and exercise performance in older adults, completely independent of structured exercise regimens.
- •Reduces systemic inflammation by clearing damaged mitochondria before they can leak mitochondrial DNA and reactive oxygen species into the cytosol, which would otherwise trigger the NLRP3 inflammasome.
- •Shows profound joint-protective properties in preclinical models by enhancing mitochondrial function in chondrocytes, suggesting a novel metabolic approach to managing age-related cartilage degradation.
- •Activates key cellular longevity pathways, including the NAD+ and sirtuin axes, functionally mimicking aspects of caloric restriction and deep fasting at the cellular level.
- •Maintains a highly favorable safety and tolerability profile even at maximal studied doses, making it one of the most promising emerging interventions in the longevity and healthspan space.
Basic Information
- Name
- Urolithin A
- Also Known As
- Mitopure3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one
- Category
- Postbiotic / Mitophagy Inducer
- Bioavailability
- Urolithin A demonstrates excellent oral bioavailability when administered as a direct supplement, bypassing the need for microbiome conversion. Following ingestion, it is rapidly absorbed in the small intestine, conjugated in the liver (primarily via glucuronidation and sulfation), and distributed to highly vascularized tissues including skeletal muscle and brain. Peak plasma concentrations are typically reached within 2 to 4 hours of ingestion.
- Half-Life
- The plasma half-life of supplemental Urolithin A is estimated to be between 12 and 16 hours. Because of its extensive phase II metabolism, circulating levels consist largely of its glucuronide and sulfate conjugates, which act as a reservoir, gradually deconjugating to deliver the active parent compound to target tissues.
Primary Mechanisms
Direct induction of mitophagy through the stabilization of PINK1 and subsequent recruitment of Parkin to damaged mitochondria
Upregulation of genes involved in mitochondrial biogenesis, ensuring replacement of cleared organelles
Activation of the SIRT1 pathway, mimicking the metabolic effects of caloric restriction
Suppression of the NLRP3 inflammasome by preventing the cytosolic leakage of mitochondrial DNA
Enhancement of cellular NAD+ levels through optimization of mitochondrial respiratory efficiency
Modulation of the gut-liver axis by improving intestinal barrier integrity and reducing endotoxemia
Quick Safety Summary
Clinical trials have utilized doses ranging from 250 mg to 1,000 mg per day. The 500 mg daily dose is standard for general mitochondrial support, while 1,000 mg daily is frequently employed in trials targeting significant improvements in muscle strength and physical endurance in older populations. These doses have been universally well-tolerated over periods up to 4 months.
Pregnancy and breastfeeding, due to an absence of specific safety data, Pediatric populations, pending further developmental safety studies, Severe hepatic impairment, which may unpredictably alter phase II conjugation and clearance, Concomitant severe acute infection, where mitochondrial dynamics are rapidly shifting
Overview
Urolithin A represents a paradigm shift in our understanding of dietary supplements, transitioning from essential nutrients to microbiome-derived, highly targeted cellular modulators. It is not naturally present in any food source. Instead, it is a postbiotic—a metabolite created exclusively by specific strains of gut bacteria (such as Gordonibacter urolithinfaciens) when they ferment ellagitannins, complex polyphenols abundant in pomegranates, walnuts, pecans, and various berries. However, human clinical studies have revealed a critical biological bottleneck: only 30 to 40 percent of the adult population possesses the requisite microbiome ecology to produce meaningful amounts of Urolithin A, regardless of how much pomegranate juice they consume. This disparity in microbiome capability renders direct supplementation of Urolithin A an essential strategy to guarantee systemic exposure to its profound health benefits, completely bypassing the unpredictability of gut fermentation.
The primary pharmacological significance of Urolithin A lies in its unparalleled ability to induce mitophagy. Mitochondria, the cellular powerhouses, accumulate oxidative damage over time. In a youthful, healthy cell, a rigorous quality control process called mitophagy identifies these failing organelles, encapsulates them in autophagosomes, and degrades them, recycling their components. As humans age, this process critically declines. Defective mitochondria accumulate, producing less ATP and more damaging reactive oxygen species, eventually leaking mitochondrial DNA into the cytosol—a powerful trigger for systemic inflammation. Urolithin A chemically restarts this stalled mitophagy process. By acting as a molecular signal that mimics cellular energy stress, it forces the cell to clear the dead weight of dysfunctional mitochondria, clearing the way for the biogenesis of fresh, highly efficient organelles.
The clinical translation of this mechanism is most vividly observed in skeletal muscle. Sarcopenia, the age-related loss of muscle mass and function, is fundamentally driven by mitochondrial failure within muscle fibers. Rigorous, double-blind, placebo-controlled human trials have demonstrated that Urolithin A supplementation at 500 mg to 1,000 mg daily significantly increases muscle strength, notably in the legs, and improves overall physical endurance in older adults. Remarkably, these functional gains occur independently of any structured exercise program, indicating that Urolithin A is capable of rescuing muscle performance solely by optimizing the underlying cellular energetics. For athletes and younger adults, this same mechanism translates to accelerated recovery, reduced muscle damage, and sustained peak power output.
Beyond musculoskeletal health, Urolithin A is emerging as a comprehensive anti-aging and longevity intervention. By clearing damaged mitochondria before they can trigger the NLRP3 inflammasome, Urolithin A serves as a potent upstream anti-inflammatory agent. This mechanism has profound implications for joint health, where Urolithin A has been shown to protect chondrocytes from metabolic failure and halt the progression of osteoarthritis in preclinical models. Furthermore, its ability to cross the blood-brain barrier and induce mitophagy in neurons positions it as a highly promising neuroprotective agent against age-related cognitive decline. By simultaneously addressing mitochondrial dysfunction, cellular senescence, and chronic inflammation, Urolithin A targets the most fundamental hallmarks of the aging process.
Core Health Impacts
- • Skeletal muscle strength and endurance: Clinical trials consistently demonstrate that Urolithin A supplementation significantly improves muscle strength, notably in the hamstrings and skeletal muscles, and increases aerobic endurance in older adults. These physical improvements are achieved by rejuvenating the mitochondrial pool within muscle fibers, allowing for greater ATP production and delayed fatigue, even in the absence of a concurrent exercise protocol.
- • Cellular aging and senescence: The accumulation of damaged mitochondria is a primary hallmark of aging and a driver of the senescence-associated secretory phenotype (SASP). By aggressively inducing mitophagy, Urolithin A clears these dysfunctional organelles, restoring youthful cellular energetics and reducing the intracellular oxidative stress that accelerates the aging process.
- • Joint health and cartilage preservation: Emerging evidence suggests Urolithin A protects against osteoarthritis by specifically enhancing mitophagy in chondrocytes. Damaged mitochondria in joint tissue fail to produce sufficient energy for matrix repair and instead generate inflammatory signals. Urolithin A restores chondrocyte metabolism, reducing the degradation of articular cartilage in preclinical models.
- • Cognitive function and neuroprotection: Neurons are exquisitely sensitive to mitochondrial dysfunction due to their massive energy demands. Urolithin A crosses the blood-brain barrier and has been shown to reduce neuroinflammation, clear defective mitochondria in brain tissue, and improve memory and cognitive readouts in animal models of Alzheimer's disease and age-related cognitive decline.
- • Metabolic health and insulin sensitivity: Mitochondrial dysfunction in skeletal muscle and liver tissue is a root cause of insulin resistance. By refreshing the mitochondrial population, Urolithin A improves cellular glucose handling and lipid oxidation, offering protective effects against diet-induced obesity and metabolic syndrome.
- • Exercise recovery: By optimizing mitochondrial efficiency and reducing the accumulation of reactive oxygen species during intense physical exertion, Urolithin A accelerates recovery times. It reduces delayed-onset muscle soreness and helps maintain peak power output during repeated bouts of strenuous activity.
- • Immune system aging: The age-related decline in immune function, termed immunosenescence, is closely tied to mitochondrial exhaustion in T cells and macrophages. Urolithin A restores the metabolic flexibility of these immune cells, potentially improving immune surveillance and reducing the chronic baseline inflammation associated with aging.
Gene Interactions
Key Gene Targets
ATG7
Urolithin A is a gut metabolite that triggers mitophagy, a specialized form of autophagy heavily dependent on ATG7 function. Urolithin A fundamentally requires the ATG7-mediated lipidation of LC3 to successfully engulf damaged mitochondria.
BNIP3L
A microbial metabolite studied for its potent ability to induce BNIP3L-mediated mitophagy and improve muscle health. Urolithin A upregulates BNIP3L (NIX) expression, directing the autophagosome specifically to the failing mitochondrial membrane.
FUNDC1
Urolithin A is a potent natural inducer of mitophagy that has been shown to enhance the FUNDC1 signaling pathway. It supports the receptor-mediated targeting of mitochondria during hypoxic or metabolic stress.
Safety & Dosing
Contraindications
Pregnancy and breastfeeding, due to an absence of specific safety data
Pediatric populations, pending further developmental safety studies
Severe hepatic impairment, which may unpredictably alter phase II conjugation and clearance
Concomitant severe acute infection, where mitochondrial dynamics are rapidly shifting
Drug Interactions
P-glycoprotein (P-gp) substrates: Urolithin A may act as a mild competitive inhibitor, potentially altering the absorption of drugs reliant on P-gp efflux
BCRP (Breast Cancer Resistance Protein) substrates: Potential modulation of transport could affect levels of certain statins or chemotherapeutics
CYP3A4 substrates: Theoretical mild competitive interaction at the hepatic level during initial first-pass metabolism
UGT1A1 substrates: Competition for glucuronidation pathways could theoretically slow the clearance of drugs like irinotecan or certain NSAIDs
OATP1B1 transport inhibitors: May alter the hepatic uptake and subsequent conjugation of Urolithin A
Warfarin: As with many polyphenolic derivatives, theoretical monitoring of INR is advised when initiating supplementation
Common Side Effects
Generally recognized as highly safe and devoid of significant side effects
Occasional mild gastrointestinal upset, including nausea or loose stools, particularly when initiated at the 1,000 mg dose on an empty stomach
Transient headache in a very small minority of users
Studied Doses
Clinical trials have utilized doses ranging from 250 mg to 1,000 mg per day. The 500 mg daily dose is standard for general mitochondrial support, while 1,000 mg daily is frequently employed in trials targeting significant improvements in muscle strength and physical endurance in older populations. These doses have been universally well-tolerated over periods up to 4 months.
Mechanism of Action
Direct Induction of Mitophagy
The most profound and scientifically validated mechanism of Urolithin A is its potent, direct induction of mitophagy. As cells metabolize energy, mitochondria inevitably suffer oxidative damage. Mitophagy is the highly specific cellular quality-control process that identifies, isolates, and degrades these damaged mitochondria before they can harm the cell. Urolithin A chemically triggers this process by stabilizing PINK1 on the outer mitochondrial membrane of failing mitochondria. This recruits the Parkin protein, which ubiquitinates the organelle, flagging it for destruction. The autophagosome then engulfs the defective mitochondrion, utilizing the ATG7 lipidation complex to seal the structure, followed by lysosomal degradation. By aggressively clearing this cellular dead weight, Urolithin A forces the cell to synthesize new, highly efficient mitochondria, fundamentally resetting the metabolic age of the tissue.
Suppression of the NLRP3 Inflammasome
Urolithin A acts as a powerful upstream anti-inflammatory agent by interrupting the primary trigger of age-related sterile inflammation (inflammaging). When damaged mitochondria are not cleared efficiently, they lose membrane integrity and leak mitochondrial DNA (mtDNA) and reactive oxygen species (ROS) directly into the cellular cytosol. The cell interprets this cytosolic mtDNA as a danger signal, identical to a viral infection, which immediately triggers the assembly of the NLRP3 inflammasome. This inflammasome massive unleashes pro-inflammatory cytokines like IL-1beta and IL-18. By ensuring the rapid clearance of failing mitochondria via mitophagy, Urolithin A intercepts this process at the source, preventing the mtDNA leakage and effectively silencing the NLRP3 inflammasome before it can initiate systemic inflammation.
Activation of SIRT1 and Longevity Pathways
Beyond mitochondrial clearance, Urolithin A acts as a caloric restriction mimetic by activating key longevity signaling networks. It has been shown to increase the expression and activity of SIRT1, the NAD+-dependent deacetylase central to cellular stress resistance and lifespan extension. SIRT1 activation promotes the deacetylation of PGC-1alpha, the master regulator of mitochondrial biogenesis, ensuring that the mitochondria destroyed by mitophagy are rapidly replaced with fresh organelles. This SIRT1 activation, combined with AMPK pathway stimulation, shifts the cell from an anabolic, growth-focused state into a highly efficient, repair-and-maintenance mode, closely replicating the metabolic signature of fasting.
Cartilage and Joint Preservation
In joint tissue, chondrocytes exist in a relatively hypoxic environment and rely heavily on precise metabolic tuning to maintain the extracellular matrix. Age-related osteoarthritis is increasingly viewed as a metabolic failure of chondrocytes driven by mitochondrial dysfunction. Urolithin A targets this specific pathology by restoring mitophagy in joint cartilage. By clearing dysfunctional mitochondria, it prevents the chondrocytes from shifting into a pro-inflammatory, matrix-degrading phenotype. Preclinical models demonstrate that Urolithin A reduces the expression of matrix metalloproteinases (MMPs), preserves cartilage thickness, and reduces joint pain, offering a disease-modifying approach to joint aging rather than mere symptom management.
Clinical Evidence
Muscle Strength and Physical Endurance
The clinical data supporting Urolithin A for muscle health in humans is definitive and highly significant. In a randomized, double-blind, placebo-controlled trial involving older adults (published in JAMA Network Open), supplementation with 1,000 mg of Urolithin A for two months led to a statistically significant improvement in muscle endurance, specifically measuring the number of muscle contractions until fatigue. A subsequent trial in middle-aged adults (published in Cell Reports Medicine) demonstrated that four months of 1,000 mg daily significantly increased absolute muscle strength, particularly in the hamstring muscles, and improved peak oxygen oxygen consumption (VO2 max). Crucially, these profound improvements in physical function occurred in cohorts that did not alter their exercise routines, proving that Urolithin A directly enhances inherent muscle capacity by optimizing the mitochondrial power grid.
Biomarkers of Cellular Health
Human clinical trials have successfully validated the mechanism of action in vivo. Muscle biopsies taken from subjects before and after Urolithin A supplementation show a clear, dose-dependent upregulation of gene signatures associated with mitochondrial biogenesis and mitophagy. Furthermore, plasma analyses from these subjects reveal significant reductions in circulating acylcarnitines and ceramides, which are established biomarkers of mitochondrial inefficiency and metabolic gridlock. This molecular evidence confirms that the physical improvements seen in muscle strength are the direct result of fundamentally improved cellular metabolism.
Recovery from Exercise-Induced Damage
For younger demographics and athletes, Urolithin A accelerates recovery from intense mechanical stress. High-intensity exercise heavily taxes the mitochondrial pool, generating massive amounts of ROS that contribute to delayed-onset muscle soreness (DOMS) and prolonged fatigue. By clearing these exhausted mitochondria immediately post-exercise and reducing the subsequent inflammatory cascade, Urolithin A allows for faster restoration of peak power output. Clinical data indicates that systemic inflammation markers, including C-reactive protein (CRP), are significantly dampened following strenuous exertion in subjects supplemented with Urolithin A.
Neuroprotection and Cognitive Aging
While human clinical trials on cognition are currently ongoing, the preclinical evidence for Urolithin A in neurodegenerative disease is highly compelling. Neurons demand immense amounts of ATP and are exquisitely vulnerable to mitochondrial failure. In murine models of Alzheimer’s disease, Urolithin A supplementation restored mitophagy in the hippocampus, reduced neuroinflammation, and decreased the accumulation of amyloid-beta plaques. Treated animals showed significant rescue of spatial memory and cognitive flexibility. By preserving mitochondrial integrity in neural tissue, Urolithin A addresses a foundational driver of cognitive decline.
Dosing Guidance
The clinically validated dosing parameters for Urolithin A are clearly established. A daily dose of 500 mg is recommended for general cellular health, proactive longevity support, and maintenance of mitochondrial quality control. For targeted interventions aiming to significantly improve muscle strength, enhance aerobic endurance, or recover from sarcopenia, the higher dose of 1,000 mg daily is required, as utilized in the most impactful human clinical trials. Urolithin A should be taken consistently for a minimum of 4 to 8 weeks to allow for cellular remodeling, ideally consumed with a meal containing dietary fat to maximize intestinal absorption of the compound. Split dosing (500 mg morning and evening) may be utilized to maintain steady-state plasma concentrations throughout the day.
Maximizing Urolithin A Efficacy
Do not rely on pomegranate juice to achieve therapeutic levels of Urolithin A, as the majority of individuals lack the necessary gut bacteria for conversion.
Pair Urolithin A with consistent exercise or resistance training; while it improves muscle function independently, the combination of optimized mitochondria and mechanical loading is highly synergistic.
Combine with NAD+ precursors (like NMN or NR) to provide the biochemical fuel required for the newly synthesized mitochondria to operate at peak efficiency.
Take with a meal that includes healthy fats (like olive oil or avocado) to improve the intestinal absorption of this polyphenolic derivative.
Consider an 8-12 week loading phase at 1,000 mg daily if targeting specific muscle recovery or age-related weakness, followed by a 500 mg maintenance dose.
Urolithin A is highly complementary to fasting protocols, as both interventions independently stimulate deep cellular autophagy and mitophagy.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark foundational study demonstrating that Urolithin A prevents the accumulation of dysfunctional mitochondria with age, extends lifespan in nematodes, and significantly improves exercise capacity in aging rodents.
The first-in-human clinical trial confirming the safety, bioavailability, and biological efficacy of direct Urolithin A supplementation, demonstrating clear upregulation of mitochondrial gene expression in human skeletal muscle.
A highly significant clinical trial showing that 1,000 mg daily of Urolithin A for 4 months significantly increased muscle strength and aerobic endurance in middle-aged adults without any changes to their exercise routine.
Preclinical study demonstrating that Urolithin A can rescue muscle function in severe genetic models of Duchenne muscular dystrophy, highlighting its profound capacity to restore mitochondrial integrity under extreme metabolic stress.
Important study showing that Urolithin A protects against osteoarthritis by enhancing mitophagy in chondrocytes, reducing the production of inflammatory mediators that drive cartilage destruction.
A comprehensive review summarizing the pleiotropic effects of Urolithin A across multiple tissues, firmly establishing its role as a cross-functional longevity intervention targeting the hallmarks of aging.
Preclinical evidence indicating that Urolithin A crosses the blood-brain barrier and reduces neuroinflammation and apoptosis by clearing damaged mitochondria in neural tissues.
Pharmacokinetic analysis confirming that only a minority of humans possess the necessary microbiome (specifically Gordonibacter strains) to produce Urolithin A, validating the necessity of direct supplementation.